Skip to content

Safety and Efficacy of Ivabradine Hydrochloride in Hemodialysis Patients with Chronic Heart Failure

Safety and Efficacy of Ivabradine Hydrochloride in Hemodialysis Patients with Chronic Heart Failure - Safety and Efficacy of Ivabradine Hydrochloride in Hemodialysis Patients with Chronic Heart Failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045871
Enrollment
50
Registered
2021-10-26
Start date
2021-06-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients with chronic heart failure whose resting heart rate is 75 beats per minute or higher

Interventions

Ivabradine hydrochloride

Sponsors

Nippon Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. patients with chronic heart failure in sinus rhythm and a resting heart rate of 75 beats per minute or greater at the time of consent 2. patients receiving standard therapy for chronic heart failure including beta-blockers at the time of consent (including beta-blocker intolerant patients) 3. male or female, 20 years of age or older at the time of consent 4. patients undergoing hemodialysis for more than 12 weeks at the time of consent. 5. patients who have given their written consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1. patients with a history of hypersensitivity to any component of ivabradine hydrochloride 2. patients with unstable or acute heart failure 3. patients with cardiogenic shock 4. patients with severe hypotension (systolic blood pressure less than 90 mmHg or diastolic blood pressure less than 50 mmHg) 5. patients with atrial fibrillation 6. patients with sinus failure syndrome, sinoatrial block, or third degree atrioventricular block 7. patients with severe hepatic dysfunction 7) Patients with severe hepatic dysfunction (Child-Pugh C) 8. patients receiving the following drugs: ritonavir-containing products, josamycin, itraconazole, clarithromycin, cobicistat-containing products, indinavir, voriconazole, nelfinavir, saquinavir, telaprevir 9. patients who are pregnant, lactating, may be pregnant or plan to become pregnant 10. patients who are receiving verapamil or diltiazem 11. patients who are scheduled to undergo surgical treatment during the study period 12. 12. patients who require a substitute.

Design outcomes

Primary

MeasureTime frame
Change in resting heart rate from baseline to 12 weeks post-dose

Countries

Japan

Contacts

Public ContactSayuri Kawasaki

Nippon Medical School Department of Nephrology

k-sayuri@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026